DUBLIN – Shire plc's newly approved plasma kallikrein inhibitor Takhzyro (lanadelumab-flyo) has, in the eyes of some analysts, the potential to reshape the hereditary angioedema (HAE) treatment landscape because of its combination of efficacy, safety and tolerability, and convenience.